Prostaglandins (PGs) are formed by a sequential series of three enzymatic reactions: release of arachidonic acid (AA) from membrane phospholipids by phospholipases, conversion of AA to an unstable endoperoxide intermediate PGH 2 by cyclooxygenase (COX), and, finally, isomerization of PGH 2 to bioactive prostanoids, including prostaglandin E 2 (PGE 2 ), prostacyclin (PGI 2 ), Prostaglandin F 2α (PGF 2α ), Prostaglandin D 2 (PGD 2 ), and thromboxane A 2 (TXA 2 ), by distinct terminal synthases. COX is best known as the molecular target of nonsteroidal anti-inflammatory drugs such as aspirin. 1 These drugs have been used traditionally as analgesics for centuries and are some of the world's most widely used drugs. The seminal work by Sir John Vane delineated the mechanism by which aspirin exerts its anti-inflammatory, analgesic, and antipyretic actions. 1 COX-2 exists in two isoforms, the constitutive COX-1 and the inducible COX-2; the two forms share 66% homology in amino acid sequence and similar enzymatic properties, but differ markedly with respect to cellular expression pattern and regulation.
STATE OF THE ART
Prostaglandins (PGs) are formed by a sequential series of three enzymatic reactions: release of arachidonic acid (AA) from membrane phospholipids by phospholipases, conversion of AA to an unstable endoperoxide intermediate PGH 2 by cyclooxygenase (COX), and, finally, isomerization of PGH 2 to bioactive prostanoids, including prostaglandin E 2 (PGE 2 ), prostacyclin (PGI 2 ), Prostaglandin F 2α (PGF 2α ), Prostaglandin D 2 (PGD 2 ), and thromboxane A 2 (TXA 2 ), by distinct terminal synthases. COX is best known as the molecular target of nonsteroidal anti-inflammatory drugs such as aspirin. 1 These drugs have been used traditionally as analgesics for centuries and are some of the world's most widely used drugs. The seminal work by Sir John Vane delineated the mechanism by which aspirin exerts its anti-inflammatory, analgesic, and antipyretic actions. 1 COX-2 exists in two isoforms, the constitutive COX-1 and the inducible COX-2; the two forms share 66% homology in amino acid sequence and similar enzymatic properties, but differ markedly with respect to cellular expression pattern and regulation.
Among terminal PG synthases, PGE synthase (PGES) specifically catalyzes the conversion of PGH 2 to PGE 2 . To date, at least three major forms of PGES have been identified. They are designated membrane-associated PGES (mPGES)-1, mPGES-2, and cytosolic PGES (cPGES). mPGES-1 was cloned from human cells as microsomal glutathione S-transferase 1-like 1 (MGST1-L1) whose PGE synthesis activity was dependent on glutathione. 2 mPGES-1 couples with COX-2 to mediate PGE 2 production in response to inflammatory stimuli and mPGES-1 deletion blunts pain and inflammatory responses. The established role of mPGES-1 in the inflammatory response has prompted interest in development of mPGES-1 inhibitors as the next generation of analgesics. 3, 4 Besides inflammatory cells, mPGES-1 is constitutively expressed in a variety of tissues, including adipose tissues, stomach, spleen, and kidney. Increasing evidence suggests a potential role of this enzyme in regulation of sodium and water balance and vascular tone. [5] [6] [7] [8] [9] A number of studies examine the effect of mPGES-1 deletion on angiotensin II (Ang II)-induced hypertension and yield variable results. mPGES-1 −/− mice on a mixed background and an inbred C57/BL6 background develop accelerated hypertensive response to chronic Ang II infusion. 7 However, another study using the same C57 background observes no impact of mPGES-1 deletion on the blood pressure (BP) response. 10 Facemire et al. generated mPGES-1 −/− mice on two inbred backgrounds, DBA/1lacJ and 129/SvEv. 11 On the 129 background, BP was significantly higher in mPGES-1 −/− mice than wild type controls at baseline and also during Ang II infusion. In contrast, on the DBA background, mPGES-1 -/-mice have normal baseline BP and also similar hypertensive response to Ang II infusion as compared with wild type controls. The data clearly suggest that mPGES-1 modifies Ang II-induced hypertension depending on the genetic background. Along this line, mPGES-1 deletion impairs aldosterone escape 12 and exacerbates the hypertensive response to deoxycorticosterone acetate-salt. 6 mPGES-2 is a second mPGES that was originally purified from bovine heart and subsequently cloned. It is a 43-kDa protein containing a unique N-terminal hydrophobic domain, which determines the association with Golgi membrane; proteolysis leads to a mature, N-terminally truncated form of 33 kDa. A third enzyme is cPGES that was originally identified from rat brain as a cytosolic glutathione-dependent PGES. It is identical to p23, which is a steroid hormone receptor/hsp90-associated protein. Both mPGES-2 and cPGES possess PGES activity in vitro. However, neither mPGES-2 nor cPGES deletion results in a measurable decrease in PGE 2 levels in tissues known to express these enzymes. [13] [14] [15] These findings do not support the contention that mPGES-2 or cPGES is a PGE 2 synthase. Thus, it appears likely that mPGES-1 may represent the only enzymatic pathway capable of producing PGE 2 in vivo.
The biologic action of PGE 2 is mediated by G proteincoupled E-prostanoid receptors designated EP 1 , EP 2 , EP 3 , and EP 4 . These four subtypes of EP receptors couple to distinct signaling pathways. In general, the EP 1 receptor signals via intracellular Ca 2+ and phosphatidylinositol-bisphosphate hydrolysis, whereas the EP 2 and EP 4 receptors are coupled to Gs and signal by intracellular cAMP. The EP 3 receptor is more complex in that it exists in multiple splice isoforms, which display differential coupling to distinct signaling mechanisms via Gi (inhibition of cAMP formation), Gs (stimulation of cAMP formation), and Gq (stimulation of intracellular Ca 2+ release). 16 In general, EP 1 /EP 3 receptors are vasoconstrictive and prohypertensive whereas EP 2 /EP 4 receptors are vasodilatory and antihypertensive.
Depressor Action of pge 2 general vasodilator action of pge 2 PGE 2 is a potent vasodilator, although in some circumstances it can be a vasoconstrictor. At whole organism level, intravenous administration of PGE 2 and PGE analogs produces a hypotensive effect. This effect is rapid and is observed within 20 s of drug infusion; it is also transient and mean arterial pressure recovers to baseline within 170 s after PGE 2 administration. 17 This short duration of action is due to the efficient metabolism of PGE 2 in the venous blood of the lung. In many vascular preparations including rabbit saphenous vein, mouse aortic ring, hamster uterus, piglet saphenous vein, rabbit ductus arteriosus, human pulmonary vein, human middle cerebral artery, and rabbit ear artery, PGE 2 directly relaxes the tissues preconstricted with KCl or norepinephrine, with a potency almost two orders of magnitude higher than that of the activation of PGI 2 (IP) or PGD 2 (DP) receptors. " [18] [19] [20] [21] [22] [23] The vasodilatory action PGE 2 is also observed in resistance vessels such as pig pial arterioles 24 and canine renal juxtamedullary arterioles. 25 However, in other vascular beds PGE 2 induces vasoconstriction. In rings of human internal mammary arteries, which are frequently used for coronary artery bypass graft surgery, PGE 2 induces vasoconstriction via EP 3 receptors. 26 This study suggests that EP 3 antagonism may offer a new therapeutic intervention to increase vascular graft patency. In addition, PGE 2 is shown to induce smooth muscle contraction in rat mesentery artery. 27 renAl Action of pge 2 pge 2 regulation of renal hemodynamics
The status of the intrarenal circulation is an important determinant of body fluid and BP homeostasis. It is known that COX inhibiting nonsteroidal anti-inflammatory drugs do not produce major disturbances in renal blood flow and glomerular filtration rate at basal condition. However, under certain pathophysiological conditions, such as congestive heart failure, cirrhosis with ascites, and nephrotic syndrome, these drugs can cause a catastrophic decrease in glomerular filtration rate in these patients. [28] [29] [30] [31] The vascular action of PGE 2 intrarenally depends on the type of blood vessels with vasodilatory action in the preglomerular afferent arterioles, distal interlobular arteries, and medullary vasa recta but contrasting to little action in the postglomerular arterioles; 32, 33 in some instances, PGE 2 causes vasoconstriction. The overall vasodilatory action of PGE 2 may help sustain renal hemodynamic function under certain pathological conditions.
The microcirculation of the renal medulla plays a pivotal role in the long-term control of BP, although it represents only a small fraction of the total renal blood flow. For example, nitric oxide (NO) can exert a profound influence on BP control by modulation of renal medullary blood flow. The reduction of renal medullary blood flow by chronic intramedullary infusion of l-NAME leads to sodium retention and salt-sensitive hypertension. 34 Conversely, the elevation of renal medullary blood flow by chronic intramedullary infusion of NO synthase (NOS) substrate l-arginine prevents the development of salt-sensitive hypertension in the Dahl salt-sensitive rat. [35] [36] [37] Emerging evidence suggests that PGE 2 , similarly to NO, may regulate renal medullary blood flow, thereby determining salt sensitivity. Chronic salt loading induces a marked increase in COX-2 expression in the rat medulla and chronic intramedullary infusion of COX-2 inhibitor leads to salt-sensitive hypertension. 38 Further evidence supports PGE 2 as an important mediator of the antihypertensive action of renal medullary COX-2. PGE 2 attenuates the constriction in isolated perfused vasa recta preconstricted with endothelin or Ang II. 39, 40 In anesthetized uninephrectomized mice, acute intramedullary PGE 2 infusion increases urine volume and urine sodium excretion. 41 This natriuretic response is likely the result of increased renal medullary blood flow, although the contribution from the direct tubular effect is possible.
pge 2 regulation of tubular transport
Intravenous PGE 2 administration to healthy dogs increases renal blood flow and induces a significant increase in urinary sodium excretion. 42 When PGE 2 and PGI 2 were infused into the renal artery of dogs, both compounds elevated renal blood flow to a similar extent, but PGE 2 induced a much larger increase in urinary sodium excretion than PGI 2 . 43 october 2012 | VoLUMe 25 NUMber 10 | AMERICAN JOURNAL OF HYPERTENSION These findings suggest that PGE 2 may have a direct action on tubular function in addition to affecting renal hemodynamics. A significant number of microperfusion studies demonstrate that PGE 2 directly inhibits NaCl reabsorption in the collecting duct (CD) and the thick ascending limb, 44, 45 although other investigators were unable to demonstrate an effect on the thick ascending limb or the CD in the similar setting. 46 Most of these studies use the basolateral application of PGE 2 . Interestingly, luminal application of PGE 2 produces a similar inhibitory effect on sodium transport in isolated perfused rabbit CD. 47 This finding appears to be physiologically or pathologically relevant since PGE 2 is present in the urine in nanomolar concentrations and its excretion is increased in the states of sodium loading and congestive heart failure.
pge 2 regulation of renal nerve activity
It is increasingly recognized that renal sympathetic nerve plays a pivotal role in fluid and BP homeostasis. Renal denervation reduces arterial pressure in various animal models of hypertension. 48 More importantly, bilateral renal denervation in patients with resistant hypertension results in a long-term reduction in arterial pressure. 49 In addition to a rich supply of sympathetic nerves, the kidney has abundant afferent sensory innervation, located primarily in the renal pelvic wall. A series of studies by Kopp et al. demonstrate that afferent renal nerve activity interacts with efferent renal sympathetic nerve activity, forming a feedback system termed the renorenal reflexes that have become an integrative part of the renal nerve circuit for the control of sodium balance and BP. [50] [51] [52] [53] The functional interaction between the two types of nerve fibers is supported by the anatomic evidence that sympathetic efferent nerve fibers and afferent sensory nerve fibers often run separately but intertwined in the same nerve bundles in the renal pelvic wall. In a simplest form, the feedback system exists in such a way that increased efferent renal sympathetic nerve activity or increasing renal pelvic pressure leads activation of afferent renal nerve activity that in turn limits the increase of efferent renal sympathetic nerve activity so that efferent renal sympathetic nerve activity can be maintained at low level. PGE 2 has been implicated to serve as an important activator of afferent renal nerve activity. Increasing renal pelvic pressure or bradykinin activates protein kinase C, which leads to increases in renal pelvic release of PGE 2 via induction of COX-2. PGE 2 activates the AC/cAMP/PKA transduction pathway, with a resultant increase in substance P release and increases in afferent renal nerve activity. 54, 55 pressor Action of pge 2 central pge 2 
and sympathoactivation
In a sharp contrast to the above-described vasodilator and antihypertensive action of intravenously administered PGE 2 , centrally administered PGE 2 via injection or infusion to the cerebral ventricles in anesthetized or awake rats elicits dramatic pressor responses accompanied by tachycardia, hyperthermia, and antidiuresis and causes increases in plasma norepinephrine and epinephrine, plasma renin activity (PRA), and plasma vasopressin (AVP). [56] [57] [58] [59] [60] Increasing evidence suggests that the hypertensive effect of central PGE 2 is mediated by the sympathetic nervous system. In this regard, the pressor response is significantly attenuated by pretreatment with phenoxybenzamine and by cervical section of the spinal cord. 58 In line with the changes in plasma catecholamines, recordings of splanchnic nerve activity demonstrate increased sympathetic neural firing following intracerebroventricular (ICV) PGE 2 . 58 In contrast, a large body of evidence demonstrates that PGE 1 and PGE 2 inhibit the release of norepinephrine from sympathetic nerve endings and also suppresses the constrictor response of the effector cells to nerve stimulation, and may serve as a break against sympathoactivation in the peripheral tissues. 61, 62 Therefore, the E series of PGs can exert either positive or negative influence on sympathoactivation depending on the type of tissues.
In addition to the sympathetic nervous system activation, the increased AVP release may also contribute to the hypertensive effect of ICV PGE 2 . In the perfused ventriculo-cisternal system of anaesthetized dogs, PGE 2 infusions elevate plasma AVP levels; in additional experiments, ICV injection of indomethacin decreased the plasma AVP concentration by ~50%. 63 The observations that hypophysectomy and the AVP antagonist, d(CH2)5Tyr(Me) AVP both effectively attenuate the pressor response to ICV PGE 2 suggest a role of AVP. 59 Interestingly, the pressor response is completely abolished by the combination of the AVP antagonist and phenoxybenzamine, suggesting that the pressor effect of ICV PGE 2 is the result of increased sympathetic nervous system activity and AVP release. The elevated PRA in response to ICV PGE 2 may suggest the involvement of the renin-angiotensin system. However, pretreatment with captopril is without an effect, thus ruling out Ang II-dependent rise in BP. 59 pge 2 and renin PGE 2 has been implicated to play a role in the pathogenesis of renin-dependent hypertension such as renovascular hypertension (RVH) by mediating the renin response to renal ischemia. Imanish et al. examined the effect of aspirin on BP in patients with unilateral RVH vs. those with essential hypertension. 64 These investigators found that in patients with RVH, PGE 2 concentration in the renal vein plasma from the stenotic kidney was elevated compared with the concentration from the normal kidney or in the aortic plasma; PRA was changed in parallel with the PGE 2 levels. In contrast, PGE 2 levels were similar between the left and right renal veins in patients with essential hypertension. Intravenous administration of aspirin lowered BP by 10 mm Hg, accompanied with parallel suppression of PGE 2 and PRA levels at all sites in patients with RVH. Conversely, aspirin treatment did not improve, but deteriorate BP control in patients with essential hypertension. 64 The above-mentioned clinical observations are supported by some animal studies demonstrating BP lowering effects of nonsteroidal anti-inflammatory drugs in rats with RVH. Indomethacin decreased BP and PRA in the rat model of RVH produced by complete ligation between the origin of renal arteries and it had no effect on BP when the left kidney was removed at the time of ligation. 65 In two kidneys, one clip hypertensive (2K1C) rats, COX-2 was upregulated in both kidney, but to a greater extent in the clipped kidney. 66 Moreover, COX-2 deletion or COX-2 inhibitors reduce renin secretion in response to maneuvers including low-salt intake, angiotensin-converting enzyme inhibition, angiotensin AT1 receptor antagonism, and reduced renal perfusion pressure. [67] [68] [69] [70] [71] [72] However, functional studies using COX-2 inhibitors in 2K1C hypertensive rats have yield conflicting results. The selective COX-2 inhibitor SC58236 decreased renin production and release and lowered BP in RVH. 73 In contrast, another selective COX-2 inhibitor celecoxib failed to affect BP or urinary aldosterone levels in this model despite the improvement of renal interstitial fibrosis. 74 Among the five major prostanoids, PGE 2 , and PGI 2 were shown to directly stimulate renin secretion in isolated juxtaglomerular cells through elevation of intracellular cAMP, the major signaling mediator of renin expression and secretion. 71, 72 Evidence is also available to support an in vivo role of PGE 2 in regulation of renin secretion. In this regard, exogenous PGE 2 , when chronically infused to the dog kidney, induced increases in PRA and BP; the hypertension induced by intrarenal PGE 2 infusion was renin-dependent since the BP was remarkably reduced by saralasin or an angiotensinconverting enzyme inhibitor. 75 The characterization of mPGES-1 allows investigations of the role of endogenously produced PGE 2 in renin regulation. Anatomic evidence is available to suggest colocalization of mPGES-1 with COX-2 in the cortical thick ascending limb and the macula densa, raising a possibility that mPGES-1 may functionally couple with COX-2 to produce PGE 2 in the juxtaglomerular apparatus for regulation of renin secretion. 76 Moreover, expression of macula densa mPGES-1, similarly to COX-2, was greatly increased in response to low-salt diet and angiotensin I-converting enzyme inhibition in rabbit kidneys. 77 However, unlike COX-2 deletion, mPGES-1 deletion has failed to affect the renin response to furosemide, which is known to stimulate renin secretion via inhibition of Na + -K + -2Cl − cotransporter type 2 in the macula densa. 9 This observation argues against a functional role of mPGES-1 in renin regulation although more thorough investigations of this topic are apparently needed in the future studies.
In addition to renin regulation, abundant evidence demonstrates that PGE 2 at nanomolar concentrations stimulates aldosterone release from cultured adrenal zona glomerulosa cells almost at the similar potency as Ang II. 78 The stimulation of aldosterone release in response to PGE 2 arises from the increased conversion of cholesterol to pregnenolone in the early step of aldosterone biosynthesis. The detailed signaling mechanism responsible for PGE 2 regulation of aldosterone release is unclear, but appears to involve cAMP-mobilizing EP 2 or EP 4 receptors. 78, 79 roles of ep 1 /ep 3 
receptors in Bp regulAtion
The EP 1 receptor was originally described as a smooth muscle constrictor. 80 This receptor is generally coupled to an intracellular calcium signal, a common pathway leading to vasoconstriction by Ang II, endothelin-1, and TXA 2 . In some vascular beds, such as tail artery and mesenteric arteries, and cerebral arteries, concomitant activation of EP 1 and EP 3 receptors is responsible for PGE 2 -induced constriction via phosphatidylinositol pathway. [81] [82] [83] Consistent with the vasoconstrictive property, the EP1 −/− mice exhibit a blunted pressor response to acute or chronic Ang II infusion. 84 In this study, the effect of an EP 1 selective antagonist SC51322 on hypertension was also tested in spontaneously hypertensive rats (SHR). The EP 1 antagonism not only reduced BP in SHR but also blocked the acute pressor effect of the EP 1/ EP 3 agonist sulprostone in mice. 84 The consistent results obtained using genetic and pharmacological approaches demonstrate an overall prohypertensive role of the EP 1 receptor. A recent study also suggests that activation of EP 1 receptors is responsible for the increased vascular tone and the development of hypertension in db/ db mice. 85 However, the selective EP 1 antagonist ONO-8713 failed to affect BP in stroke-prone spontaneously hypertensive rats (SHRSP) despite improvement of renal injury. 86 Contrary to the above-described vasoconstrictive and prohypertensive action of EP 1 receptors, the direct tubular action of EP 1 receptor activation is natriuretic and therefore is antihypertensive. In isolated, perfused rabbit cortical CD, PGE 2 inhibits sodium transport via elevated intracellular cytosolic calcium 87 and this action is largely ascribed to activation of EP 1 receptors. 45 The physiological significance of natriuretic action of renal EP1 receptors in the context of the overall prohypertensive action of this subtype remains elusive.
Accumulating evidence suggests an important role played by EP 3 88 This observation has been extended by Zhang et al. who tested the effects of central administration of various EP antagonists in a similar experimental setting. 89 PGE 2 -elicited cardiovascular and renal sympathoexcitatory responses were significantly reduced by pretreatment with the EP 3 antagonist; the EP 1 and EP 4 antagonists had little or no effects. The independent studies respectively using EP agonists and antagonists consistently demonstrate that EP 3 receptor is a dominant EP subtype responsible for the central sympathoexcitatory effect of PGE 2 . In a general agreement with this notion, EP 3 −/− mice show reduced brain injury after cerebral ischemia. 90 Together, these results suggest that EP 3 receptor activation may largely account for the pressor effect of central PGE 2 via eliciting the sympathoexcitatory response and that EP 3 inhibitors may hold promise to develop into novel therapies for the management of hypertension and stroke. Of note, the pressor action of EP 3 receptors also occurs in peripheral vascular beds including rat mesentery artery, rat tail artery, guinea-pig aorta, human pulmonary artery, and murine renal vasculature. 27, [91] [92] [93] [94] The relative contribution of peripheral versus central action of EP 3 receptors to increased BP is unclear.
Within the kidneys of rabbits and mice, EP 3 receptors are abundantly detected in the renal medulla and localized to medullary thick ascending limb and the CD, the two important nephron sites for the natriuretic and diuretic actions of PGE 2 . Activation of EP 3 receptors also inhibits AVP-induced cAMP accumulation. However, EP 3 receptor deletion in mice does not produce a major influence on renal function or BP. 92 
roles of ep 2 /ep 4 receptors in Bp regulAtion
The increase of intracellular cAMP through a Gs coupled pathway is a classical mechanism for vasorelaxation. EP 2 /EP 4 receptors via this pathway have the potential to control vascular tone and BP. An important role of EP 2 receptors in BP regulation is suggested by the hypertensive phenotype of EP 2 −/− mice at baseline and following a high-salt diet. While EP 2 −/− mice had a modest increase of BP at baseline, these animals developed profound hypertension when fed a high-salt diet. Moreover, the hypertension was quickly reversed by switching to normal salt diet and is re-established by resumption of the high-salt diet, establishing salt sensitivity. 95 In light of the well recognized vasodepressor action of EP 2 receptors, it is conceivable that the loss of this action may account for the hypertensive phenotype in EP 2 −/− mice. This notion is supported by the observation that in response to acute PGE 2 infusion, EP 2 −/− mice developed hypertension rather than hypotension seen the wild-type mice. It is somewhat puzzling, however, that evidence from studies using the aortic ring preparation suggests a primary role of the EP 4 , but not the EP 2 receptor in mediating PGE 2 -induced relaxations. 21 Since conduit vessels were used in these preparations, a possibility still exists that EP 2 receptor may be more important in resistance vessels. Recently, Chen et al. examined the role of EP 2 in the natriuretic response to intramedullary infusion of PGE 2 in mice. 41 Intramedullary, PGE 2 infusion to anesthetized, uninephrectomized mice produced natriuresis and diuresis, an effect that was recapitulated by intramedullary infusion of the EP 2 agonist butaprost. Strikingly, the natriuresis was absent in EP 2 −/− mice. 41 These results underscore an important role of the EP 2 receptor in mediating the renal natriuretic action of PGE 2 . It is unknown whether the natriuretic effect of EP 2 receptor activation is the result of altered renal medullary blood flow or tubular sodium transport.
As discussed above, in vitro evidence supports an essential role of EP 4 receptors in mediating PGE 2 -elicited vasodilation in isolated aortic rings. 21 The dilator action of EP 4 receptor activation is dependent on endothelium derived NO production via increased eNOS activity as a result of dephosphorylation at Thr 495 . NO results in guanylyl cyclase-dependent accumulation of cGMP that leads to vasorelaxation in aortic rings. This study also presents in vivo evidence that the hypotensive response to acute PGE 2 infusion is blunted in eNOS −/− mice. However, despite the well-defined vasodepressor action of EP 4 receptors, the underlying signaling mechanism and the functional role of this subtype in long-term BP regulation in vivo remains unclear.
pge 2 inActivAtion
The steady-state level of active prostanoids is determined by the relative rates of biosynthesis and inactivation. Thus, it is equally important to understand PG-degrading processes. PGs are rapidly cleared in a single passage through any of the vascular beds, including those of lung. This may serve as a key mechanism to ensure that PGs act in the vicinity of the site of synthesis, exerting autocrine, or paracrine functions. In this way, the local determination of the signal can prevent undesired action at a distance. Compared with the overwhelming information regarding the PG biosynthesis pathway, much less is known about the inactivation pathway. The inactivation of PGs has been proposed to involve two major steps: (i) selective uptake across plasma membrane via PG transporter (PGT) and (ii) oxidation inside the cell via NAD + -dependent 15-hydoxyprostaglandin dehydrogenase). [96] [97] [98] [99] PGT is broadly expressed in many cell types with most abundant expression in the lung, suggesting that this transporter may be responsible for the single-pass metabolic clearance of PGs through that vascular bed in the lung. Recently, a structurally distinct PG-specific organic transporter (OAT-PG) in the OAT group of the SLC22 family has been identified. 100, 101 OAT-PG has high affinity and selectivity for PGE 2 , similar to PGT. Unlike PGT, however, OAT-PG is exclusively expressed in the kidney and further localized to the basolateral membrane of proximal tubules where 15-hydoxyprostaglandin dehydrogenase is expressed mostly in the cytosol. 100 This anatomic evidence suggests functional coupling between transporters and metabolic enzymes in the clearance of extracellular PGs in the kidney.
conclusion PGE 2 plays a diverse role in BP regulation depending on the site of action. Rodent studies demonstrated that centrally administered PGE 2 elevates BP, but systemically administered PGE 2 produces a hypotensive effect; PGE 2 also modulates BP via affecting renin secretion. In most cases, the net effect of PGE 2 is determined by the balance between the pressor action of EP 1 /EP 3 receptors and the depressor action of EP 2 /EP 4 receptors. The preferential activation of a particular EP subtype relies on the setting of BP regulation. For example, EP 3 receptors play a dominant role in hypertension development induced by central PGE 2 infusion through sympathoactivation whereas EP 1 receptors mediate increased BP in response to Ang II infusion and in SHR via vasoconstriction. On the other hand, the EP 2 receptor deficiency leads to salt-sensitive hypertension due to impaired renal natriuresis. An in-depth understanding of PGE 2 signaling pathway will offer unique opportunity for development of novel antihypertensive interventions targeting specific EP receptors in a specific setting.
